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ABSTRACT
NPM1/nucleophosmin is frequently overexpressed
in various tumors, although the oncogenic role of
NPM1 remains unclear. Here we revealed the link
between NPM1 and nuclear factor-B (NF-B), a
master regulator of inflammation. We found that
NPM1 knockdown decreased NF-B-mediated tran-
scription of selected target genes by decreasing the
recruitment of NF-B p65 to the gene promoters.
NPM1 is directly associated with the DNA binding
domain of p65 to enhance its DNA binding activ-
ity without being a part of the DNA–NF-B com-
plex. This result suggests that NF-B requires the
chaperone-like function of NPM1 for DNA binding.
Furthermore, we demonstrated that NPM1 was re-
quired for efficient inflammatory gene expression in-
duced by tumor necrosis factor alpha (TNF-) and
lipopolysaccharide in fibroblasts and macrophages.
The NF-B-mediated invasion of breast cancer cells
was significantly decreased by NPM1 knockdown.
Our study suggests a novel mechanistic insight into
the NF-B-mediated transcription and an oncogenic
role of NPM1 in both tumor cells and the tumor micro-
environment through the regulation of NF-B.
INTRODUCTION
Tumorigenesis in human occurs through a multistep pro-
cess in which normal human cells progress through a se-
ries of premalignant phenotypes until an invasive cancer
emerges (1). During tumor development, cancer cells ac-
quire distinctive and complementary hallmark capabilities
that enable tumor growth and metastatic dissemination (2).
In addition to cancer cells, tumors create the tumor micro-
environment by recruiting normal cells that form the tumor-
associated stroma to support tumor development, and pro-
gression as well as its drug resistance (3). Therefore, the tu-
mor micro-environment has been considered to be a thera-
peutic target for anti-tumorigenesis treatment.
A transcription factor, nuclear factor-B (NF-B), plays
a key role in tumor initiation, promotion, progression and
metastasis (4–7). In addition to its oncogenic functions in
cancer cells, NF-B contributes to tumorigenesis through
the activation of inflammatory cells in the tumor micro-
environment because of its central role in the immune sys-
tem. Therefore, NF-B has been suggested to be a key link
between inflammation and cancer. NF-B was originally
discovered as a site-specific DNA-binding protein complex
that binds to the enhancer element of the immunoglobulin
(Ig) kappa light-chain of activated B cells (8). The mam-
malian NF-B family contains the following five proteins:
(i) p65 (RelA); (ii) c-Rel; (iii) RelB; (iv) p50; and (v) p52,
which function as homo- or hetero-dimers to control gene
transcription (9). The most abundant form of the NF-B
complex contains the p65–p50 heterodimer that regulates
the genes including those for cytokines, chemokines, adhe-
sionmolecules and enzymes that produce secondary inflam-
matory mediators.
Achieving precise and sufficient gene regulation by NF-
B requires specific post-translationalmodifications and in-
teractions with cofactors (10). Indeed, it was predicted that
the original size of the native NF-B complex from nuclear
extracts is much larger than that of theNF-B p65–p50 het-
erodimer. Moreover, the native NF-B complexes have a
higher affinity for the Ig B DNA motif than the reconsti-
tuted p65–p50 heterodimer does (11,12), which highlights
the importance of cofactors for NF-B DNA binding. It
has been reported that ribosomal protein S3 (13), Sam68
(14), telomerase (15) and cyclin dependent kinase 6 (16) di-
rectly associate with the NF-B complex and enhance its
DNA binding activity. It was also observed that a nucleolar
protein nucleophosmin/B23/NPM1 interacts with NF-B
and regulates the expression of the SOD2 gene (17).
NPM1 is a highly abundant phosphoprotein that mainly
resides in the nucleolus, but continuously moves between
the nucleolus, the nucleoplasm, and the cytoplasm (18). We
have identified NPM1 as a factor stimulating adenovirus
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chromatin remodeling and studied its functions in unin-
fected cells (19). It is a multifunctional protein involved
in various cellular processes such as ribosome biogenesis
(20,21), sperm chromatin remodeling (22), centrosome du-
plication (23) and DNA repair (24). Biochemically, NPM1
shows the histone chaperone activity (25), which is required
for the regulation of chromatin structure. Histone chaper-
ones bind directly to histones for their transfer to DNA
to assemble chromatin without being incorporated into the
chromatin. Much of the interest in NPM1 has been bol-
stered by the fact that it is directly implicated in tumorigen-
esis. On the one hand, the genetic alterations of the NPM1
gene have been detected in various hematological malignan-
cies, and strikingly, NPM1 is one of themost frequentlymu-
tated genes in acute myeloid leukemia (26). On the other
hand, NPM1 is over-expressed in various solid tumors and
has been proposed as a tumor marker (27). The expression
levels of NPM1 have been reported to be regulated by the
oncogeneMYC (28) and to correlate with tumor recurrence
and progression (29). However, the oncogenic functions of
NPM1 remain still poorly understood in spite of the obser-
vations that NPM1 overexpression in tumor cells increases
cell growth and proliferation, and inhibits cell differentia-
tion and apoptosis (27).
Although the NF-B pathway has been studied exten-
sively and some of the cofactors of NF-B have been iden-
tified, the molecular mechanisms by which the NF-B ac-
tivity is regulated by cofactors during cancer progression
and inflammatory responses are not well understood. In the
present study, we aimed to clarify the connection between
two oncogenic proteins, NPM1 and NF-B, to provide a
new insight into the molecular basis of tumorigenesis. Our
findings are important for two main reasons: (i) NF-B, a
master regulator of inflammation, requires the chaperone-
like activity of an oncogenic protein NPM1 for its functions
and; (ii) two oncogenic factors, NPM1 andNF-B, are sug-
gested to cooperatively regulate tumor progression through
cancer cells and the tumor micro-environment.
MATERIALS AND METHODS
Plasmid constructs
NPM1 expression plasmids have been described previ-
ously (30). To construct pGEX2T-NPM1-N, cDNAs
for NPM1-N was cut out from pET14b-NPM1-N
(30) by BamH I and cloned into the same site of
pGEX2T vector. The p65/RelA, RelB, c-Rel, and
p50 genes were cloned by PCR using primer sets 5′-
ATGCGGATCCATGGACGAACTGTTCCCCCT-3′ and
5′- ATGCGGGATCCTTAGGAGCTGATCTGACTCA-
3′, 5′-AAAGAATTCATGCTTCGGTCTGGGCCAGC-3′
and 5′-AAAGAATTCCTACGTGGCTTCAGGCCCCG-
3′, 5′-AAAGGATTCATGGCCTCCGGTGCGTATAA
-3′ and 5′-AAAGAATTCTTATACTTGAAAAAATT
CAT -3′, and 5′-AAAGAATTCATGGCAGAAGA
TGATCCATA-3′ and 5′-AAACTCGAGTAGGTTC
CATGCTTCATCCCAG-3′, respectively. The ampli-
fied p65, RelB, c-Rel, and p50 cDNA fragments were
subcloned into the BamH I-digested, EcoR I-digested,
BamH I and EcoR I-digested, and EcoR I and Xho
I digested pcDNA3.1-Flag vector. The p65 and p50
cDNAs were also cloned into pcDNA3-HA vector. To
construct vectors expressing p65 deletion mutants, dele-
tion mutant cDNAs were cloned by PCR using primers
5′-ATGCGGATCCATGGACGAACTGTTCCCCCT-
3′ and 5′-AAAGGATCCTTAAGAAAGGACA
GGCGGCAGGC-3′ for p65-N1 (a.a.1–180), 5′-
AAAGGATCCCATCCCATCTTTGACAATCG-
3′ and 5′-AAAGGATCCTTAAGAAGCTGAG
CTGCGGGAAG-3′ for p65-N2 (a.a.181–340), 5′-
AAAGGATCCGTCCCCAAGCCAGCACCCCA-3′ and
5′-ATGCGGGATCCTTAGGAGCTGATCTGACTCA-
3′ for p65-C (a.a. 341–551), p65 forward primer and
p65-N2 reverse primer for p65-N (a.a.1–340), p65-N2 for-
ward and p65 reverse primers for p65-N2C (a.a.181–551),
the amplified cDNAs were subcloned into the BamH I sites
of pcDNA3.1-Flag and pET14b vectors. All the plasmids
were confirmed by DNA sequencing.
Animals, cell culture, transfection and reagents
C57BL/6J-ApcMin/+ mice were purchased from the Jack-
son Laboratory. The Min pedigree was maintained by
mating C57BL/6J wild-type females with C57BL/6J-
ApcMin/+males, genotype analysis was performed using a
PCR assay as described (31). Colon adenomas were devel-
oped by administration of 2% dextran sulfate salt in drink-
ing water for 7 days during 5th week of age. Mice were
sacrificed at 8 weeks of age and subjected to histological
analyses. BDF-1 mice were purchased from CLEA Japan,
Inc. HeLa, HEK293T, BT-20, MDA-MB-157, MDA-MB-
231,MDA-MB-436 cells, and p53−/− and p53−/−NPM1−/−
mouse embryonic fibroblast (MEF) cells were cultured
in DMEM supplemented with 10% heat-inactivated fe-
tal bovine serum (FBS) at 37◦C with 5% CO2. Primary
macrophages were prepared from wild-type BDF-1 mice
(10-week old) injected with 3.84% (w/v) thioglycollate 3
d after injection. PBS (5 ml) was injected into peritoneal
cavity and recovered. Cells were centrifuged and seeded
in RPMI1640 medium (GIBCO) supplemented with 10%
FBS, and incubated at 37◦C for 0.5 h. Non-adherent cells
were removed by wash with PBS, and cells were maintained
in the same medium.
Transfection and reagents
Transfection of plasmid DNA and siRNAs were performed
by GeneJuice (Novagen) and Lipofectamine RNAiMAX
(Life technologies), respectively, according to the manu-
facturer’s instructions. Stealth RNAs for negative controls
and human NPM1 were described previously (32). Mouse
NPM1 (s124573) and human NF-B p65 (HSS109159)
were obtained fromLife technologies. Antibodies used were
NPM1 (Invitrogen), Flag tag (M2, Sigma Aldrich), p65
(ab7970, Abcam), I-B (sc-371, Santa Cruz) and -actin
(sc-47778, Santa Cruz). Recombinant human TNF- (PE-
PROTECH) and Lipopolysaccharide (LPS) (Sigma) were
commercially available.
Preparation of proteins
Purifications of GST-tagged proteins and his-tagged pro-
teins were described previously (33). For purification of
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Flag-tagged proteins, HEK 293T cells transfected with ap-
propriate expression vectors were suspended in buffer A
(0.1% Triton X-100, 20 mM Tris-HCl pH7.9, 10 mM KCl,
1.5 mM MgCl2, 0.5 mM phenylmethylsulfonyl fluoride
(PMSF)) containing 400 mM NaCl on ice for 10 min and
rotate at 4◦C for 30 min followed by centrifuge at 15k rpm,
4◦C for 15 min. The supernatants were recovered and di-
luted with twice volumes of buffer A without NaCl. The
cell extracts were incubated with anti-Flag M2 affinity gels
(SIGMA–ALDRICH) for 2 h at 4◦C and then washed
by buffer B (0.1% Triton X-100, 50 mM Tris-HCl pH7.9,
0.5 mM PMSF) containing 300 mM NaCl. The proteins
bound with the resin were eluted with buffer A contain-
ing 150mMNaCl and Flag peptide (SIGMA–ALDRICH),
dialyzed against buffer H (20 mM Hepes–NaOH pH 7.9,
50 mM NaCl, 0.5 mM ethylenediaminetetraacetic acid, 1
mM Dithiothreitol (DTT), 0.1 mM PMSF and 10% Glyc-
erol).
Immunoprecipitation and GST-pull down assay
HeLa cells were treated with or without TNF- and the
cell lysates were prepared. The extracts were subjected to
immunoprecipitation with control Ig or anti-p65 antibody,
and immunoprecipitated proteins were separated by sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) and detected by western blotting. For GST-pull
down assays, GST, GST-NPM1 or GST-NPM1 deletion
mutants was incubated with glutathione-sepharose beads in
buffer A for 45 min and washed with buffer A twice. The
beads were mixed with Flag-p65, RelB or c-Rel and incu-
bated at 4◦C for 2 h followed by extensive washing with the
same buffer. Proteins were eluted from the beads by an SDS
sample buffer, separated by SDS-PAGE, and visualized by
CBB staining and western blotting.
Reporter assay
HeLa cells (3 × 104 per well) were seeded in 24-well plates
and transfected with 80 ng of pNF-B-TA-Luc (Firefly lu-
ciferase) and 20 ng of pTA-RL (Renilla luciferase) at 48 h af-
ter transfection with siRNA for NPM1 or negative control.
Sixteen hours after transfection, cells were treated with 20
ng/ml TNF- for different time courses as described in the
legend. Luciferase assay was performed using Renilla Lu-
ciferase Assay System kit (Promega Corporation, USA) ac-
cording to the manufacturer’s instructions. The sane exper-
iments were performed with p53−/− and p53−/−NPM1−/−
MEFs.
RT-qPCR and chromatin immunoprecipitation (ChIP) as-
says
Total RNA was extracted using RNeasy Kit (Qiagen) ac-
cording to the manufacturer’s instructions. cDNA was pre-
pared from purified RNA (1 g) by using ReverTraAce
(Toyobo) with oligo dT primer. Real-time PCR was car-
ried out in triplicate with primers (sequences are shown in
Supplementary Table S1) by using SYBR Green Realtime
PCRMasterMix-Plus (Toyobo) in the Thermal CyclerDice
Real-Time PCR system (TaKaRa). ChIP was performed
with HeLa cells treated with or without TNF-. Cells were
fixed with 1.4% formaldehyde at room temperature for 10
min, the whole cell lysates were sonicated to generate DNA
fragments 200–1000 base pairs in length. The sonicated
lysates were used for ChIP with anti-p65, anti-NPM1 or
IgG control antibodies. After washing, the complexes were
eluted, protein–DNA crosslink was reversed, andDNAwas
purified and used for quantitative PCR. Primer sequences
used for PCR were shown in Supplementary Table S2.
EMSA
Double-stranded oligonucleotide probes containing the B
sequences derived from immunoglobulin (Ig), IL-8 and
NR4A2 genes (see Figure 6D) were used. The mutant Ig B
(5′-AGTTGAATCCACTTTCCCAGG-3′) were also used
for electrophoretic mobility shift assay (EMSA). For Ig B
sequence, the oligonucleotide was [32P]-labeled and used for
EMSA assay as previously described (13). Briefly, p65 or
p50 protein (20 ng/sample) was incubated with the purified
GST,GST-NPM1orHis-NPM1protein at 25◦C for 30min,
followed by additional incubation with [32P]-labeled Ig B
(WT) or Ig B (Mut) oligonucleotide at 25◦C for 30 min.
Samples were resolved on a 6% native PAGE in 0.5xTBE
buffer. For supershift analyses, recombinant proteins were
preincubated with 0.2 g of antibodies for 20 min on ice
prior to the addition of labeled probes.
Immunofluorescence, proximity ligation assays, immunohis-
tochemistry
The cells on cover slips were fixed with 3% paraformarde-
hyde in PBS, permeabilized in PBS containing 0.5% Triton
X-100 and incubated with anti-NPM1 and p65 antibodies
diluted with PBS containing 0.5% non-fat dry milk. Local-
ization of proteins was visualized with secondary antibod-
ies conjugating with AlexaFluor dyes (Molecular Probes).
During final wash with PBS containing 0.1% Triton X-
100, DAPI DNA staining dye was added and incubated for
15min at room temperature. In situ proximity ligation assay
(PLA) kit (Sigma-ALDRICH) was used to detect protein–
protein interaction in fixed cells according to the manufac-
turer’s instructions. PLA signals were quantitatively ana-
lyzed by the image processing software Imaris (Carl Zeiss
microimagining). Localization of proteins, DNA and PLA
signals was observed under confocal microscope (LSMEX-
CITER; Carl Zeiss Microimaging, Inc.). For immunohis-
tochemistry assay, Apcmin/+mice (12-weeks old) were given
2% (w/v) DSS in drinking water for 1 week, then changed
to normal drinking water for 2 weeks. Colon tissues from
the mice were cut and opened, fixed in phosphate-buffered
10% formalin and embedded in paraffin and cut into 5-
m sections. The sections were dewaxed, rehydrated and
immersed in 3% hydrogen peroxide for 20 min to quench
endogenous peroxidase activity. Antigen retrieval was per-
formed at 95◦C for 20 min in sodium citrate buffer (pH 6.0).
The sections were incubated with blocking buffer (PBS sup-
plemented with 2% goat serum and 1% bovine serum albu-
min) for 1 h, anti-NPM1 or p65 antibodies for 1 h, a bi-
otinylated secondary antibody for 45 min and peroxidase-
conjugated streptavidin solution for 45 min. Protein local-
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ization was visualized with 3, 3-diaminobenzidine and sec-
tions were lightly counterstained using Gill’s haematoxylin.
Microarray hybridization and data analysis
HeLa cells were incubated with NPM1 or control siRNA
for 72 h and treated without or with 20 ng/ml TNF-
for 2 h. Total RNA was then isolated using RNeasy Kit
(Qiagen) according to the manufacturer’s instructions. The
sense-strand cDNA was prepared using Ambion WT Ex-
pression Kit from 200 ng total RNA. The cDNA was then
fragmented and labeled using the Affymetrix GeneChip
WT Terminal Labeling Kit. The fragmented and labeled
cDNA was injected to the Gene Arrays 1.0 ST and in-
cubated at 45◦C with 60 rpm for 17 h. The hybridized
samples were washed and stained using Affymetrix flu-
idics station 450.GeneChipswere scanned usingAffymetrix
GeneArray Scanner 3000 7G Plus. All kits were ob-
tained from Affymetrix (Santa Clara, CA, USA) and
experiments were performed according to the manuals.
Raw data were analyzed using the rma() function in R-
Bioconductor (34) package ‘affy’ (35,36) with default set-
ting. Background correcting was processed by the RMA
(robust multichip averaging) (37), the data were normal-
ized by quantiles and the signal intensity of each probe
set was obtained by the method medianpolish. The an-
notation of probe sets was performed by Bioconductor
hugene10sttranscriptcluster.db. The microarray data are
available at the NCBI Gene Expression Omnibus (GEO)
under accession number GSE81785. Gene ontology anal-
ysis was performed using DAVID (The Database for An-
notation, Visualization and Integrated Discovery) (http://
david.abcc.ncifcrf.gov/) (38,39).
Matri-gel invasion assay
Invasion assays were performed using transwell chambers
(24-well insert; pore size, 8 m; Corning-Costar, Corning,
NY, USA). Transwell membrane was coated with 30 g of
matrigel and incubated at 37◦C for 3 h. MDA-MB-231 cells
(5 × 104) in 200 l of serum-free medium were seeded into
the upper chamber of the transwell and medium supple-
mented with serum was used as a chemoattractant in the
lower chamber. The cells on the upper chamber were treated
with or without TNF-, incubated for 16 h and cells that
did not invade through the pores were removed with a cot-
ton swab. Cells on the lower surface of the membrane were
fixed with methanol and stained with 0.05% crystal violet.
The stained cells were counted under a microscope (Leica
Dmi8) in three random fields/well.
RESULTS
Interaction between NPM1 and NF-B
Aprevious study showed that NPM1 interacts with theNF-
B subunits p65 and p50 (17). However, whether NPM1
also interacts with other NF-B family proteins and the
interaction is direct or not have never been examined.
We first examined the interaction between NPM1 and the
NF-B family Rel proteins, p65 (RelA), RelB and c-Rel.
Flag-tagged p65, RelB and c-Rel were purified (Figure 1A)
and a glutathione S-transferase (GST) pull down assay
was performed. All purified Flag-tagged p65, RelB and
c-Rel were more efficiently precipitated with GST-NPM1
than GST, indicating that NPM1 directly interacts with
the NF-B proteins in vitro. Flag-p65 precipitated by GST-
NPM1 was much more efficient than RelB and c-Rel (Fig-
ure 1B), suggesting that NPM1 preferentially associates
with p65. We also found that NPM1 directly interacted
with p65 and p50 (Supplementary Figure S1). We next
confirmed the endogenous interaction between NPM1 and
the NF-B p65 subunit by co-immunoprecipitation with
anti-p65 antibody in HeLa cells treated without or with
TNF- (Figure 1C). Endogenous NPM1 was weakly co-
immunoprecipitated with p65 without TNF- treatment,
whereas the co-immunoprecipitated NPM1 was increased
upon TNF- treatment. Furthermore, in situ PLA using
antibodies for both NPM1 and p65 revealed that NPM1
interacted with p65 mainly in the nucleus (Figure 1D, top
panels). Treatment of cells with TNF-, which activates
the NF-B pathway, dramatically enhanced the interaction
(Figure 1D, bottom panel and Figure 1E). The PLA sig-
nals were mainly detected in the nucleoplasm, indicating
that this is where the interaction between p65 and NPM1
occurred. These results indicated that NPM1 interacts with
NF-B in the cells and this interaction is enhanced by treat-
ment of cells with TNF-. Because NPM1 is mainly local-
ized in the nucleolus, we tested whether NPM1 localization
was changed upon treatment of cells with TNF-. HeLa
cells stably expressing enhanced green fluorescent protein
(EGFP)-NPM1 were treated with TNF- and the localiza-
tions of p65 and EGFP-NPM1 were examined (Figure 1F).
p65was translocated to the nuclei 15min after TNF- treat-
ment. We found that although the interaction between p65
andNPM1 occurred in the nucleoplasm (Figure 1D and E),
TNF- treatment did not clearly change the localization of
EGFP-NPM1.
NPM1 regulates NF-B-dependent gene transcription
Wenext examined the effect of RNAi-mediated knockdown
of NPM1 on the expression of NF-B-dependent reporter
gene expression in HeLa cells. NPM1 siRNA significantly
decreased the total amount of NPM1 compared with the
non-specific (NS) control siRNA (Figure 2A). The reporter
activity was found to be decreased by NPM1 knockdown
even in the absence of TNF-. As expected, TNF- treat-
ment induced the NF-B-driven luciferase activity in NS
siRNA-treated cells, but this induction was significantly de-
creased in NPM1 siRNA-treated cells (Figure 2B).
We performed microarray analysis to comprehensively
analyze the effect of NPM1 knockdown on the NF-B-
dependent gene expression induced by TNF- treatment
in HeLa cells. We found that without TNF- treatment,
288 genes were upregulated (>1.5-fold) and 359 genes were
downregulated (<0.667-fold) by NPM1 knockdown (Sup-
plementary Figure S2B and Table S4), suggesting that
NPM1 is involved in the regulation of a variety of genes.
Upon stimulation with TNF-, 77 genes were upregulated
(>1.5-fold) and 13 genes were downregulated (<0.667-fold)
(Supplementary Figure S2A and Table S3). In addition,
in TNF- treated cells, NPM1 knockdown decreased the
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Figure 1. Interaction between NPM1 and NF-B. (A) Purified NF-B proteins. Flag tagged p65, RelB and c-Rel were expressed in 293T cells, purified
with Flag-affinity gel, separated by 10% SDS-PAGE and visualized by CBB staining. (B) Direct interaction between NPM1 and the NF-B proteins.
GST pull-down assays using GST or GST-NPM1 (lanes 4–6 and 7–9) with purified Flag-p65 (RelA), -RelB or -c-Rel were performed. Flag-tagged NF-
B proteins were detected by western blotting and the GST proteins were visualized by CBB staining. (C) Immunoprecipitation assay. Cell extracts were
prepared from HeLa cells treated without or with TNF- for 30 min, and the interaction between NPM1 and p65 was analyzed by immunoprecipitation
with control Ig and anti-p65 antibody. The input (lanes 1 and 4) and immunoprecipitated (lanes 2, 3, 5 and 6) proteins were separated by SDS-PAGE and
analyzed by western blotting with anti-NPM1 and p65 antibodies. (D and E) In vivo interaction between NPM1 and p65. HeLa cells were treated with
or without 20 ng/ml TNF- for 1 h, in situ proximity ligation assays (PLAs) were performed using primary antibodies against NPM1 and p65. The PLA
signals in panel C were quantitatively analyzed by the image processing software Imaris. The average spot number per cell was calculated from randomly
selected cells (n = 20). Error bars represent ±SD, statistical significance was calculated using student’s t-test and *** indicates P < 0.001. (F) Localization
of NPM1 in TNF- treated cells. HeLa cells stably expressing EGFP-NPM1 were treated without or with TNF- (20 ng/ml) for 15 min and 60 min,
followed by immunofluorescence analysis with anti-p65 antibody and the localization of the proteins was observed by a confocal microscope. Bar at the
bottom indicates 10 m.
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Figure 2. NPM1 regulatesNF-B-dependent gene transcription. (A) Knockdown ofNPM1 inHeLa cells by siRNA treatment.Western blotting confirmed
the knockdown of NPM1 in HeLa cells. -actin is a loading control. (B) Reporter assay. HeLa cells treated with NS or NPM1 siRNAs were transfected
with p-B-uc and p-TA-RL plasmids. The cells were then stimulated without or with TNF- for 3 h and subjected to luciferase assay. The relative luciferase
activity (fold increase) is shown. Three independent experiments were performed and error bars indicate ±SD. (C andD) Microarray analyses. RNAs were
extracted from HeLa cells treated with control siRNA (chip 1 and 2) or NPM1 siRNA (chip 3 and 4) followed by stimulation without (chip1 and 3) or
with TNF- (chip 2 and 4), and subjected to microarray analyses. The Venn diagram (upper panel) shows the coding genes induced by TNF- treatment
(chip 1 versus 2), the coding genes downregulated by NPM1 knockdown in cells treated with TNF- (chip 2 versus 4) and their overlapped genes. The
overlapped 32 genes were subjected to gene ontology analysis and the list of the enriched functions is shown. Heat maps (D) depict the expression of the 32
overlapped genes (left) and the fold changes (right) between control and NPM1 knockdown cells treated with TNF- (chip 2 versus 4). The data are more
precisely shown in Supplementary Figure S2D. (E) Confirmation of the microarray data by real-time RT-PCR analyses. RT-PCR for the genes involved in
the list of (D) was performed using RNA extracted from cells treated with or without siRNAs and TNF- as indicated at the bottom. RT-PCR was also
examined for the two genes (NR4A2 and DUSP5) that were upregulated by NPM1 knockdown, three independent experiments were performed and error
bars indicate ±SD. The results were statistically analyzed by student t-test and ***, ** and * represent P < 0.001, 0.01 and 0.05, respectively.
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expression of 445 genes (<0.667-fold) and increased the
expression of 223 genes (>1.5-fold) (Supplementary Fig-
ure S2C and Table S5). Among the 77 genes upregulated
by TNF- treatment, 32 genes were downregulated (>1.5-
fold) by NPM1 knockdown (Figure 2C, upper panel) and
only two genes were upregulated (>1.5-fold) by NPM1
knockdown. When the cutoff fold-change (chip2 versus
chip4) was set to 1.2, the number of the genes downreg-
ulated by NPM1 knockdown was increased to 55, while
only seven genes were upregulated (>1.2-fold) by NPM1
knockdown (Supplementary Figure S2E and F). These re-
sults suggested that NPM1 is involved in the regulation
of most, but not all, genes stimulated by TNF- treat-
ment. The heat map shows the expression of the 32 genes
sorted by the fold change values (Figure 2D and Supple-
mentary Figure S2D) between control and NPM1 knock-
down in TNF--treated cells. Many of them are cytokines,
such as IL-8,TNF-α, and IL-6. Indeed, gene ontology (GO)
analysis of the 32 TNF--induced genes whose expressions
were downregulated (>1.5-fold) by knockdown of NPM1
showed functional enrichment in inflammation and immu-
nity such as cytokine activity, cytokine, inflammatory re-
sponse, response to wounding and defense response (Fig-
ure 2C, lower panel). To confirm the microarray analyses,
reverse transcriptase-mediated polymerase chain reaction
(RT-PCR) was performed (Figure 2E). The expressions of
eight genes (IGFL1, SELE, CCL2, RND1, PLAU, IL-8,
TNF-α, and CCL20) were confirmed to be significantly re-
duced by NPM1 knockdown. In addition, we confirmed
that the expression levels of NR4A2 and DUSP5 were
slightly increased byNPM1 knockdown. It should be noted
that the increase or decrease of those genes was observed
even in the absence of TNF- treatment. To further confirm
the specific effect of NPM1 on the NF-B pathway, we next
examined the NF-B-mediated gene expression in control
and EGFP-NPM1 expressing HeLa cell lines (Supplemen-
tary Figure S3A). Over-expression of NPM1 significantly
increased the expressions ofNF-B target genesTNF-α and
RND1 both in NS and NPM1 siRNA treated cells, whereas
those of NR4A2 and DUSP5 genes were slightly decreased
(Supplementary Figure S3B). These results support the idea
thatNPM1 is involved in the regulation ofNF-B-mediated
transcription and the effect of NPM1 knockdown on NF-
Bdependent transcription is not due to the off-target effect
of siRNA.
To explore the mechanism by which NPM1 regulates the
expression of the genes stimulated by TNF-, we examined
whether NPM1 knockdown affected the NF-B signaling
pathway such as I-B protein degradation, NF-B nuclear
translocation and NF-B recruitment to its target genes
upon stimulation byTNF-. The I-Bproteins bindNF-B
to retain it in the cytoplasm and are quickly degraded upon
stimulation by TNF- through the ubiquitin-proteasome
system to allow the nuclear translocation of NF-B. The
I-κB genes are target genes of the NF-B complex and the
I-B–NF-B complex constitutes a feedback oscillatory cir-
cuit (40). Indeed, I-Bwas quickly degraded upon TNF-
treatment and the expression was recovered within 60 min,
and the oscillatory expression was observed with peak ex-
pressions at 60 and 105 min (Figure 3A). We found that I-
B protein degradation was similarly observed 15 min af-
ter TNF- stimulation regardless of the level of NPM1 ex-
pression (lane 2). However, the pattern of oscillatory expres-
sion of I-B was changed by NPM1 knockdown, suggest-
ing that NPM1 is involved in the I-B expression. Like-
wise, the nuclear translocation of NF-B p65 upon TNF-
treatmentwas not affected by knockdown ofNPM1 (Figure
3B). We then examined whether NPM1 affected the bind-
ing of NF-B to target gene promoters by chromatin im-
munoprecipitation (ChIP). In unstimulated cells, a low but
distinct amount of p65 was detected at the promoter re-
gions of TNF-α, PLAU, IL-8, NR4A2 and DUSP5 genes.
Upon stimulation with TNF-, the binding of p65 to these
genes was significantly increased. However, NPM1 knock-
down decreased the p65 binding to the TNF-α, PLAU and
IL-8 gene promoters in both unstimulated and TNF--
stimulated cells. In contrast, the recruitment of p65 to the
promoter regions of NR4A2 and DUSP5 was not affected
by knockdown of NPM1 (Figure 3C). These results indi-
cate that NPM1 stimulates the binding of NF-B to a sub-
set of NF-B target gene promoters. We noted that the ex-
pression of NR4A2 and DUSP5 was increased by NPM1
knockdown regardless of TNF- treatment (Figure 2E and
Supplementary Figure S3), whereas the promoter binding
of p65 to these genes was not significantly affected. These
results indicate that NPM1 suppresses these genes indepen-
dent of the promoter binding of NF-B.
NPM1 enhances the DNA binding activity of NF-B
Considering the effect of NPM1 on the binding of NF-
B to target gene promoters in vivo and its direct interac-
tion with NF-B in vitro, we next examined whether NPM1
affected the binding of NF-B to the B site in vitro by
the EMSA using purified recombinant NF-B proteins and
His-NPM1 (Figure 4A). When either Flag-p65 or Flag-p50
was expressed, a homo-dimer of Flag-tagged proteins and
a minor population of a heterodimer of Flag-tagged pro-
teins and endogenous p65 or p50 were purified (lanes 2 and
3). When Flag-p50 and HA-p65 were co-expressed and pu-
rified with anti-Flag affinity gel, the Flag-p50 homodimer
and the heterodimer of Flag-p50 and HA-p65 were purified
(lane 4). All purified p50 homodimer, p65 homodimer and
p65–p50 heterodimers specifically bound to the B oligonu-
cleotide (Figure 4B, lanes 2 and 5), but not to the mutant
B oligonucleotide (lanes 3 and 6). The addition of anti-
p65, anti-Flag tag or anti-HA tag antibody induced super-
shift, thereby ensuring the binding of specificNF-Bdimers
to the B oligonucleotide (lanes 4 and 7–9). NPM1 signif-
icantly increased the binding of all NF-B dimers to the
B oligonucelotide in a dose dependent manner, whereas
NPM1 itself did not bind to the B oligonucleotide (Figure
4C).
To test whether NPM1 is included in the NF-B/DNA
complex, EMSA with or without anti-NPM1 was per-
formed (Figure 4D). The Flag-p65 homodimer and Flag-
p50–HA-p65 heterodimers were bound to the B oligonu-
cleotide, which was enhanced by NPM1 (lanes 2, 3, 6 and
7). The addition of Flag antibody, but not NPM1 anti-
body, induced a supershift of the complex containing DNA
and the NF-B proteins (lanes 4, 5, 8 and 9). Considered
together, these results indicated that NPM1 binds directly
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Figure 3. NPM1 regulates the target gene binding of NF-B, but not its nuclear translocation. (A) Effect of NPM1 knockdown on the expression level of
I-B. The amounts of I-B and -actin in HeLa cells treated with control siRNA or NPM1 siRNA after TNF- treatment were examined by western
blotting. Time (min) after TNF- treatment is shown at the bottom of the panel. (B) Localization of p65 after TNF- treatment in HeLa cells treated with
control or NPM1 siRNA. DNA was counter stained by DAPI. (C) Recruitment of p65 to its target genes. HeLa cells transfected with siRNAs as indicated
were incubated without or with TNF- for 1 h, followed by ChIP assay. The precipitated DNA amounts containing the promoter regions of the genes
listed in Figure 2D (TNF-α, PLAU and IL-8) and those of stimulated genes (NR4A2 and DUSP5) by NPM1 knockdown were quantitatively analyzed by
q-PCR. Three independent experiments were performed and error bars indicates ±SD. The results were statistically analyzed by student t-test and ***, **
and * indicate P < 0.001, 0.01 and 0.05, respectively.
to and enhances the DNA binding activity of the NF-B
proteins without being incorporated into the NF-B/DNA
complex.
To further explore whether NPM1 is incorporated into
the NF-B/DNA complex in vivo, we next performed ChIP
assays with antibodies against endogenous p65 and NPM1
(Figure 4E). The binding of p65 to thePLAU and IL-8 gene
promoters, but not to the ribosome RNA gene (rDNA), was
increased upon TNF- treatment in a time-dependentman-
ner.NPM1 showed constant binding to rDNAas previously
reported (20), but was not recruited to the PLAU and IL-8
gene promoters during the entire time course after TNF-
treatment. These results support our conclusion thatNPM1
is not included in the NF-B/DNA complex. In addition,
it is unlikely that NPM1 stimulates the p65 binding by reg-
ulating the histone density on the NF-B target genes as
a histone chaperone, because NPM1 itself does not stably
associate with the NF-B target genes.
NPM1 and B DNA compete for binding to NF-B
We next attempted to clarify the mechanism by which
NPM1 enhances the DNA binding activity of NF-B. To
this end, we first determined the NF-B binding domain
of NPM1 by a GST-pull down assay with the NPM1 dele-
tion mutant proteins (Figure 5A). A splicing variant of
NPM1/B23.1 termed B23.2 that lacks the C-terminal RNA
binding domain interacted with p65, indicating that the C-
terminal RNA binding domain is dispensable for p65 bind-
ing (Figure 5B, lane 7). Further analyses suggested that the
N-terminal oligomerization domain and acidic regionswere
also dispensable for p65 binding and the C-terminal region
termed NPM1-CR was sufficient to interact with p65 in
vitro (Figure 5B, lanes 2–6).
Next, the NPM1 binding domain of p65 was deter-
mined by immunoprecipitation assay. Flag-tagged p65 pro-
teins were expressed in 293T cells and immunoprecipitated
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Figure 4. NPM1 enhances the DNA binding activity of NF-B. (A) Purified proteins. His-tagged NPM1 and the NF-B proteins purified with Flag-
tag antibody were separated by SDS-PAGE and visualized by CBB staining. (B) EMSA with purified proteins. Purified recombinant NF-B proteins
(20 ng/sample) were analyzed by EMSA with a [32P]-labeled, double-stranded wild-type (WT) or mutant (mut) B oligonucleotides (300 fmole/sample).
Antibodies against p65, Flag-tag or HA-tag were added in the mixture as shown in lanes 4 and 7–9. (C) Effect of NPM1 on the DNA binding activity of
the NF-B proteins. Flag-p65 and Flag-p50/HA-p65 (20 ng, lanes 2–5 and 6–9, respectively) were incubated with increasing amounts of His-NPM1 (0, 50,
100 and 200 ng), followed by EMSA with [32P]-labeled probe (200 fmole/sample). The NPM1 alone (200 ng) was also incubated with the same probe (lane
1). (D) Supershift analysis with NPM1 antibody. Flag-p65 and Flag-p50/HA-p65 (20 ng, lanes 2–5 and 6–9, respectively) were incubated without or with
His-NPM1 (200 ng) and indicated antibodies, followed by EMSA. The DNA bands bound by the p65–p65, p65–p50 and p50–p50 complexes, free probes
and supershifted bands are indicated by filled arrowheads, blank arrowheads and asterisks, respectively (B–D). (E) Chromatin immunoprecipitation assay.
HeLa cells were treated with TNF- (20 ng/ml) for indicated time periods and then subjected to ChIP assays with control Ig, anti-p65 and anti-NPM1
antibodies. The rRNA gene coding region (rDNA) and the promoter regions of PLAU and IL-8 genes were analyzed by qPCR.
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Figure 5. The domain mapping of NPM1 and p65 required for their interaction. (A) Diagram of the splicing variants and truncation mutants of NPM1.
Black, light gray and dark gray boxes indicate oligomerization domain, acidic regions and the C-terminal globular domain, respectively. (B) GST-pull
down assay. GST or GST fusion proteins were incubated with purified Flag-p65 (500 ng/sample) and the bound proteins were analyzed by SDS-PAGE,
followed by CBB staining for GST proteins (bottom panels) or western blotting with anti-Flag antibody (top panels). (C) Diagram of the mutants of p65.
The N-terminal DNA binding domain, dimerization domain and the activation domain are shown by black, light gray and dark gray boxes, respectively.
(D) Immunoprecipitation analysis of the Flag-tagged p65 mutant proteins. Flag-tagged wild-ype and truncated p65 proteins were transiently expressed in
293T cells and immunoprecipitated with anti-Flag antibody. Input and immunoprecipitated proteins were analyzed by western blotting with anti-Flag and
-NPM1 antibodies.
with anti-Flag antibody followed by western blotting with
anti-NPM1 antibody (Figure 5C and D). Consistent with
the data shown in Figure 1C, NPM1 was co-precipitated
with full length p65. The N-terminal domain of p65 (p65-
N1) that contains the DNA binding domain of p65, but
not the dimer formation domain without or with the ac-
tivation domain (p65-N2 or p65-N2C, respectively), co-
precipitated with endogenous NPM1. The N-terminal do-
main with the dimer formation domain (p65-N) also effi-
ciently co-precipitated NPM1, indicating that NPM1 inter-
acts with the DNA binding domain of p65.
Because NPM1 interacts with the DNA binding domain,
we next questioned whether the N-terminal domain is suf-
ficient for NPM1 to enhance the DNA binding activity of
p65. NPM1 increased the binding of p65-N to the BDNA
in a dose dependent manner (Figure 6A and B), suggesting
that the C-terminal activation domain of p65 is dispensable
for NPM1 to enhance the DNA binding activity of p65.
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Figure 6. The chaperone-like function of NPM1 enhances the binding of p65 to specific sequences. (A) Purified proteins. His-p65-N and His-p65-C were
separated by SDS-PAGE and visualized by CBB staining. (B) Effect of NPM1 on the DNA binding activity of p65-N. His-p65-N (40 ng, lane 1–5) were
incubated with increasing amounts of His-NPM1 (0, 100, 200, 400 and 800 ng), and EMSA was performed. DNA was visualized by GelRed staining. (C)
NPM1 and DNA complete for p65-N binding. His-NPM1 (60 pmole, lanes 2–8) was incubated with increasing amounts of His-p65-N (lanes 2–5, 0, 25,
50, 100 pmole, lanes 6–9, 100 pmole), then incubated without (lanes 1–5) or with increasing amounts of B DNA (for lanes 6–8, 40, 80 and 160 pmole,
respectively). Lanes 1 and 9 indicate His-p65-N alone (100 pmole) and the mixture of His-p65-N (100 pmole) and B DNA (160 pmole), respectively.
The complexes were separated by native PAGE and visualized by CBB staining. Positions of free NPM1 are shown at the left side of the panel and the
accumulated free NPM1 is also indicated by asterisks at the right side of the lanes. (D) The binding of p65-N to different DNA probes. Three B DNA
fragments (2 pmole) derived from Ig, IL-8 and NR4A2 genes as shown at the right of the panel were incubated with increasing amounts of His-p65-N
(0, 0.5, 1, 2 pmole, lanes 1–4, 5–8 and 9–12, respectively), separated by native PAGE and visualized by GelRed staining. The B consensus sequences are
indicated by capital letters. (E) NPM1 enhances the binding of p65-N to specific B sites. The B DNA fragments as in (D) were mixed with His-p65-N
protein (0.5 pmole) pre-incubated with increasing amounts of His-NPM1 (0, 100, 200, 400, lanes 2–5, lanes 7–10, lanes 12–15), separated by native PAGE
and visualized by GelRed staining. Lanes 1, 6 and 11 indicate the kBDNA fragments without p65-N or NPM1. The intensity of the bands for p65-N-DNA
complex were quantitatively analyzed and shown at the right graph. The experiments were repeated five times and error bars indicate ±SD. Blank and
filled arrowheads in D and E show free DNA probes and the p65-N–DNA complexes, respectively.
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Given that NPM1 directly interacted with the DNA
binding domain of p65 and that NPM1 was not incor-
porated into the NF-B/DNA complex, it was speculated
that NPM1 and DNA compete for the binding to NF-B.
This speculation was first examined by gel shift assay us-
ing purified p65-N and NPM1 (Figure 6C). NPM1 is an
acidic protein and migrated to the cathode in native gel,
whereas p65-N entered the gel inefficiently (lanes 1 and 2).
The mobility of NPM1 was shifted upon addition of p65-
N in a dose dependent manner (lanes 2–5). However, the
addition of B DNA increased free NPM1 and the DNA–
p65-N complex appeared (lanes 6–8). Taken together, these
results suggest that the chaperone-like function of NPM1
is required for the efficient DNA binding of NF-B. To
further confirm this conclusion, disruption of NPM1–p65-
N complex by the B DNA oligonucleotide was exam-
ined using purified proteins and oligonucleotide (Supple-
mentary Figure S4). The p65-N protein bound to GST-
NPM1 was eluted in the supernatant in an oligonucleotide
concentration-dependent manner. Because the mutant B
DNA did not efficiently compete with NPM1 for the bind-
ing to p65-N, NPM1 transferred the p65-N protein prefer-
entially to the B DNA.
To clarify the mechanism by which NPM1 regulates a
subset of NF-B target genes, EMSA assays were per-
formed using the B site DNA fragments derived from Ig,
IL-8 and NR4A2 genes (Figure 6D). The p65-N protein
bound to all three B site DNAs with similar efficiency.
Interestingly, NPM1 significantly enhanced the binding of
p65-N to Ig and IL-8 B sites, whereas the effect of NPM1
on the binding of p65-N to the NR4A2 B site was very
low (Figure 6E). This result indicates that the B sequence
and/or the sequence around it determines the requirement
of NPM1 for the efficient p65 binding to its target sites.
NPM1 decreases the intramolecular interaction of p65
It was previously reported that the intramolecular interac-
tion between the N- and C-terminal domains of p65 blocks
the binding of CBP/p300 to the p65 protein (41). This sug-
gests that the formation of the transcription activation com-
plex is controlled by the intramolecular interaction of p65.
Considering that NPM1 interacts with the N-terminal do-
main of p65, we speculated that NPM1might compete with
the C-terminal domain of p65 for the binding to the N-
terminal domain of p65, thus decreases the intramolecu-
lar interaction of p65 to enhance the assembly of the tran-
scription activation complexes. To examine this, gel shift as-
say was performed using purified NPM1, p65-N and p65-
C (Figure 7A). Free p65-C migrated to the cathode and
the p65-C band was shifted upon addition of p65-N in its
dose-dependent manner (lane 2–5), ensuring the interac-
tion between p65-N and p65-C. Interestingly, the addition
of NPM1 increased free p65-C (lanes 6–8) and the NPM1–
p65-N complex appeared, indicating that NPM1 decreased
the intramolecular interaction between p65-Nand -C. From
these results, it is suggested that the p65 subunit of NF-B
translocated to the nuclei upon various stimuli is bound by
NPM1.NPM1 enhances theDNAbinding ofNF-B via its
chaperone-like function and simultaneously decreases the
Figure 7. NPM1 decreases the intramolecular interaction of p65. (A)
NPM1 decreases the interaction between p65-N and p65-C. His-p65-C
(lanes 2–8, 12 pmole) was incubated with increasing amounts of His-p65-
N (lanes 2–5, 0, 9, 27, 54 pmole and lanes 6–8, 54 pmole) and His-NPM1
(lanes 2–5, 0 pmol, lanes 6–8, 20, 40, 80 pmole), lane 1 indicates 54 pmole of
His-p65-N alone, lane 9 indicates 80 pmole of His-NPM1 incubated with
54 pmole of His-p65-N. Proteins were separated by native PAGE and vi-
sualized by silver staining. (B) A working model of NF-B-mediated tran-
scription regulated byNPM1. Upon stimulation, NF-B is translocated to
the nucleus where it associates with NPM1. The association of NPM1 en-
hances the DNA binding activity of NF-B and decreases the intramolec-
ular interaction of p65. NPM1 releases NF-B upon its binding to target
DNA.
intramolecular interaction of p65 to enhance the assembly
of the transcription activation complexes (Figure 7B).
Functional intersection between NPM1 and NF-B
Because NF-B is a crucial regulator of tumor formation,
progression and migration (42), and NPM1 is highly ex-
pressed in cancer cells (27), we next investigated the bi-
ological significance of the interaction between NF-B
and NPM1 in cancer. We first examined the expression of
NPM1 and NF-B in normal colon and adenomas ob-
tained from multiple intestinal neoplasia (min) mice car-
rying a mutation in the adenomatous polyposis coli gene
(Apcmin/+ mice) treated with dextran sodium sulfate, an in-
ducer of colitis (SupplementaryFigure S5AandFigure 8A).
The normal colon epithelium (lower section of the pictures)
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Figure 8. Functional intersection between NPM1 and NF-B signaling. (A) Expression and localization of NPM1 and p65 in inflammatory colon in
Apcmin/+ mice. Hematoxylin and eosin (HE) staining, and immunohistochemistry with anti-NPM1 and -p65 antibodies are shown as indicated. ‘N’ and
‘Ad’ represent normal and adenoma, respectively. Scale bars indicate 50 m. (B) Western blotting of p53−/− and p53−/−NPM1−/− MEFs with anti-NPM1
and anti- actin. (C) The NF-B-dependent reporter activity in MEFs. p53−/− and p53−/−NPM1−/− MEFs were transfected with reporter plasmids for
16 h, stimulated without or with TNF- (20 ng/ml) or LPS (1 g/ml) for 3 h, and examined for luciferase activity. The relative NF-B-driven luciferase
activity (fold increase) is shown. Three independent experiments were performed and error bars are ± SD. (D) Western blotting of mouse peritoneal
macrophages. Mouse peritoneal macrophages were transfected with NS or NPM1 siRNA for 72 h, followed by treatment with or without LPS (1 g/ml)
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showed uniform crypts, whereas the crypt structures were
disorganized in the adenomas (upper section of the pic-
tures). Hematoxylin and eosin (HE) staining clearly demon-
strated that the cells in adenomas exhibited slightly larger
nuclei, prominent nucleoli and intensely colored cytoplasm.
We found that much stronger expression of both the p65
subunit of NF-B and NPM1 was detected in adenomas
than in normal colon. Both proteins were also detected at
high levels in stromal cells. Importantly, p65 was mainly de-
tected in the nucleus in stromal cells in adenomas, suggest-
ing that NF-B was activated in stromal cells.
Given that tumor cells are associated with a hetero-
geneous mixture of stromal cells that include fibroblasts
and immune cells, it was possible that NPM1 and NF-
B cooperatively induce cancer progression by the func-
tions of stromal cells. To examine this possibility, we tested
the functional interaction between NPM1 and NF-B in
both MEFs and peritoneal macrophages. We used p53−/−
and p53−/−NPM1−/− MEFs to examine the effect of
NPM1 depletion on the NF-B-driven luciferase expres-
sion. NPM1−/− MEFs undergo cell cycle arrest due to p53
activation and can grow only when p53 is also depleted (43).
BothTNF- andLPS stimuli induced theNF-B-driven lu-
ciferase activity in p53−/− controlMEFs (Figure 8C). How-
ever, the reporter activities induced by both stimuli were sig-
nificantly lower in p53−/−NPM1−/− MEFs than those in
p53−/− control MEFs (Figure 8C). Next, mouse peritoneal
macrophages were treated with control or NPM1 siRNAs
and the expression of NPM1was examined by western blot-
ting (Figure 8D). NPM1 expression was clearly decreased
by NPM1 siRNA treatment, whereas that of actin was un-
changed. The expressions of NF-B target genes TNF-α,
IL-1β, IL-6 and IFN-β, but notGAPDH, were significantly
induced by LPS (Figure 8E, lanes 1 and 2). The induced
expressions of TNF-α, IL-1β and IFN-β were significantly
decreased by NPM1 knockdown, whereas the expression of
the IL-6 gene was not significantly affected. Considered to-
gether, our results demonstrated that NPM1 and NF-B
cooperatively regulate the inflammatory responses both in
fibroblasts and macrophages.
To address the significance of the interaction between
NPM1 and p65 in cancer, we examined the effect of NPM1
on the expression of the NF-B target genes in colon can-
cer cell line HCT-116 (Supplementary Figure S5B and C).
NPM1 depletion decreased the expression of IL-8, CCL2,
CCL20 and TNF-α, suggesting that the functional inter-
action between NPM1 and NF-B plays critical roles in
colon cancer. Furthermore, we examined the expression
level of NPM1 in various breast cancer cell lines using the
GOBO database (44), because breast cancer cells having
‘triple negative’ phenotype, namely no expression of es-
trogen receptor, progesterone receptor and ERBB2, show
constitutive activation of the NF-B activity (45). Previ-
ous study showed that NPM1 is highly expressed in nor-
mal luminal epithelial cells and its expression is induced by
hormones (46). However, among commonly used 51 breast
cancer cell lines, the expression of NPM1 was highest in
the basal B subtype cell lines that show ‘triple negative’
phenotype and exhibit a stem cell-like gene expression pro-
file (47), and was the lowest in luminal subtype cell lines
that show more differentiated and non-invasive phenotype
(Supplementary Figure S6A and B) (47). To confirm the
expression of NPM1 in basal A- or B-type breast cancer
cell lines (BT20,MDA-MB-157,MDA-MB-231 andMDA-
MB-436), RT-PCR and western blotting were performed
(Figure 8F). The results indicated that the expression of
NPM1 was the highest in MDA-MB436 cells among the
four cell lines tested. The previously determined constitu-
tive NF-B activities of these cells (45) were plotted against
NPM1 mRNA level (Figure 8G). The constitutive NF-B
activity was correlated with the expression level of NPM1,
although the expression level of p65 was not very high in
MDA-MB-436 cells (Figure 8H and G). These results sup-
port the idea that NPM1 is a positive regulator of the NF-
B complex.
Because NF-B has been reported to regulate cancer
cell migration and invasion (42), we examined the effect of
NPM1 knockdown on TNF--induced cancer cell invasion
by matrigel invasion assays using a breast cancer cell line,
MDA-MB-231 (Supplementary Figure S7 and Figure 8H).
We demonstrated that TNF- treatment significantly en-
hanced the invasion of MDA-MB-231 cells. Upon knock-
down ofNF-Bp65, the TNF- induced invasion ofMDA-
MB-231 cells was greatly reduced, indicating that the inva-
sion enhanced by TNF- was NF-B-dependent. Knock-
down of NPM1 or double knockdown of NPM1 and p65
both blocked the TNF--induced invasion, suggesting that
NPM1 regulates cancer cell invasion through enhancing
NF-B signaling. The expression level of p65 andNPM1 by
siRNA treatment was confirmed by western blotting (Sup-
plementary Figure S7A). The expression of the chemokines
CCL2 and CCL20, which have been reported to regulate
the migration of breast cancer cells (48,49), not GAPDH,
were decreased by NPM1 knockdown (Supplementary Fig-
ure S7C). Considered together, we concluded that NPM1
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
for 2 h. The extracts were subjected to western blotting with anti-NPM1 and anti- actin antibodies. (E) Expression of cytokine genes in macrophages.
Total RNAswere extracted from cells as in (D) and the expressions of cytokines (TNF-α, IL-1β, IL-6 and IFN-β) andGAPDHwere analyzed byRT-qPCR.
Three independent experiments were performed and error bars are ± SD. (F) Expression of NPM1 in breast cancer cell lines. Cell extracts (2 and 4 g of
proteins for top and middle panels, respectively) from BT-20, MDA-MB-157, MDA-MB-231 or MDA-MB-436 cells were separated by 10% SDS-PAGE
and the expression of p65, -actin and NPM1 was examined by western blotting. Total RNA was extracted and the expression of NPM1 and β-actin was
quantitatively analyzed by RT-qPCR. The amount of NPM1 mRNA was normalized by that of β-actin and shown in bottom graph. (G) Relationship
between theNF-B activity andNPM1 expression level. The constitutive NF-B activity obtained from published data (45) was plotted as a function of the
NPM1 mRNA level shown in (F). (H) Invasion activity of MDA-MB-231 cells. MDA-MB-231 cells were transfected with NS, NPM1, p65, or NPM1 and
p65 siRNAs for 48 h, seeded in transwells coated with Matrigel, and treated without or with TNF-α for 16 h. Representative images of the bottom surface
are shown in Supplementary Figure S7B. Cell number detected at the bottom surface of control siRNA-treated and non-stimulated cells was set as 1.0, and
relative cell numbers were quantitatively analyzed. Cell numbers were averages of four random microscopic fields from three independent experiments and
error bars are± SD. The results in C, E and Hwere statistically analyzed by student t-test and ***, ** and * indicates P< 0.001, 0.01 and 0.05, respectively.
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and NF-B cooperatively regulate the cancer progression
induced by the NF-B signaling.
DISCUSSION
In this study, we revealed the role of NPM1 in the NF-B
signaling pathway and examined the physiological signifi-
cance of this role. The data presented here suggest aworking
model in which NPM1 interacts with NF-B in the nucleus
to stimulate the binding of NF-B to target gene promoters.
Interestingly, NPM1 itself disassociates from NF-B once
NF-B binds to DNA (Figure 7B). NPM1 interacts with
the N-terminal DNA binding domain of p65 and competes
with DNA for the binding to p65, which results in the re-
lease of NPM1 after p65 binds to DNA. These results sug-
gest that the chaperone-like function of NPM1 is required
for the maximal transcription stimulatory activity of NF-
B. We also showed that NPM1 attenuates the intramolec-
ular interaction between the N- and C-terminal domains
of p65 (Figure 7A). The intramolecular interaction blocks
the recruitment of transcriptional coactivators CBP/p300
(41). Thus, by decreasing the intramolecular interaction of
p65, NPM1 may also enhance the interaction between p65
and CBP/p300 before p65 binds to DNA. We noted that
although the expressions of some NF-B target genes such
as PLAU and IL-8were greatly decreased by NPM1 knock-
down (Figure 2E), the recruitment ofNF-Bp65 to the pro-
moters was only decreased to about half (Figure 3C). Thus,
it is possible that NPM1 regulates both the DNA binding
and activator recruitment activities of the NF-B proteins.
Our microarray and ChIP data indicated that NPM1 reg-
ulates a subset of NF-B target genes induced by TNF-
 (Figure 2). ChIP experiments revealed that NPM1 is re-
quired for the efficient recruitment of the NF-B p65 to the
inflammatory genes, whereas p65 was able to be recruited to
the promoter regions ofNR4A2 andDUSP5 independently
of theNPM1 expression level (Figure 3C). This gene specific
regulation by NPM1 could be explained by the result that
NPM1 enhances the binding of p65 to specific B sites (Fig-
ure 6E). Although the feature of sequence to which NPM1
enhances the binding of p65 is currently unclear, the B se-
quence and/or the sequence around it affect the sequence
specificity of p65 complexed with NPM1. These results also
suggest that other NF-B cofactor(s) might be involved
in the regulation of these genes either by competing with
NPM1 to bind to NF-B or by compensating the function
of NPM1 in NPM1 knockdown cells. For example, RPS3,
cyclin-dependent kinase 6 and telomerase (13,15,16) have
been found to be cofactors of NF-B. It will be important
to understand how these cofactors, including NPM1, co-
operatively or independently regulate the NF-B functions
in inflammatory responses and cancer progression. In addi-
tion, five NF-B proteins form various homo-dimers and
hetero-dimers. Therefore, it is possible that NPM1 inter-
acts with and stimulates the activity of specific NF-B pro-
teins. It was recently shown that IL-6 expression in mouse
macrophages is regulated by the I-B–p50 complex that
binds to a cofactor Akirin2 to recruit the SWI/SNF chro-
matin remodeling complex (50). Akirin2 does not interact
with the p65 and NPM1 did not enhance the IL-6 gene ex-
pression in macrophages (Figure 8E). Therefore, it is possi-
ble that NPM1 does not associate with or affect the activity
of the I-B–p50 complex in macrophages. Consistent with
this, we demonstrated thatNPM1preferentially binds to the
canonical NF-B proteins p65 (Figure 1A and Supplemen-
tary Figure S1).
NF-B mediated transcription does not simply depend
on the amount of NF-B. The post-translational modifi-
cations and co-factors, as well as the chromatin structure
around their target genes contribute to determining theNF-
B activity. Precisely controlled NF-B activity is required
for normal cell growth and immune and inflammatory re-
sponses (51). NPM1 is broadly expressed in normal cells
and is suggested to contribute to the maintenance of ap-
propriate NF-B activity as it was shown to regulate NF-
B-mediated transcription in fibroblasts and macrophages
which are the components of tumor micro-environment
(Figure 8C–E). In addition, NPM1 may potentially con-
tribute to the oncogenic NF-B functions in cancer cells
as it regulates the NF-B mediated transcription in can-
cer cells (Figures 2 and 8) and its expression level is corre-
lated to NF-B activity in colon adenoma and breast can-
cer cell lines (Figure 8). The results that NPM1 regulated
NF-B mediated inflammatory genes in both cancer cells
and normal cells like macrophages suggest the oncogenic
role of NPM1 in both tumor cells and the tumor micro-
environment through the regulation of NF-B. Consider-
ing that NPM1 also shows other oncogenic functions inde-
pendent of NF-B, such as regulating the activity and sta-
bility of p53 and ARF, cell growth, proliferation and anti-
apoptosis, it is likely that the expression level of NPM1 is a
suitable diagnostic marker to determine the aggressiveness
of cancer cells and also a suitable target of cancer therapy.
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